Motor Neuron Disease

Motor neuron disease (MND) is a group of progressive neurodegenerative disorders that selectively destroy the upper and/or lower motor neurons, producing weakness and wasting without sensory, sphincter, or cognitive-dominant deficits. The prototype and commonest form is amyotrophic lateral sclerosis (ALS), where the combination of upper motor neuron (UMN) and lower motor neuron (LMN) signs in the same body region is the diagnostic hallmark.

Definition & Classification

MND refers to selective, progressive degeneration of motor neurons in the motor cortex (Betz cells), corticospinal/corticobulbar tracts, brainstem motor nuclei, and anterior horn cells of the spinal cord. The defining feature exploited in exams is the simultaneous presence of UMN and LMN signs with sparing of sensory pathways.

Four classic clinical variants are recognised based on which neurons predominate:

Variant	Neurons affected	Key features	Prognosis
Amyotrophic lateral sclerosis (ALS)	UMN + LMN (mixed)	Limb wasting + brisk reflexes, fasciculations, spasticity	Median survival 3–5 yrs
Progressive muscular atrophy (PMA)	Pure LMN	Wasting, fasciculations, hyporeflexia, no spasticity	Slower than ALS
Primary lateral sclerosis (PLS)	Pure UMN	Spasticity, brisk reflexes, no wasting	Best (slowest, years–decades)
Progressive bulbar palsy (PBP)	LMN of bulbar nuclei (± UMN)	Dysarthria, dysphagia, tongue wasting/fasciculations	Worst (early respiratory/aspiration death)

High-yield: ALS is the most common form (~80%). The single most useful exam clue is mixed UMN + LMN signs in the same region — e.g., a wasted, fasciculating limb (LMN) that is also hyperreflexic with extensor plantar (UMN). This combination is virtually pathognomonic.

A fifth descriptive entity, pseudobulbar palsy, reflects bilateral corticobulbar (UMN) involvement and is contrasted with bulbar (LMN) palsy in the differentials section below.

Epidemiology

• Incidence ~1–2/100,000; peak onset 55–65 years; slight male predominance.
• ~90–95% sporadic; ~5–10% familial. Of familial cases, mutations in C9orf72 (commonest, also linked to frontotemporal dementia), SOD1 (superoxide dismutase 1, the classic first-described gene), TARDBP (TDP-43) and FUS are tested.
• Riluzole-relevant pearl: ALS associated with frontotemporal dementia (FTD) clusters with C9orf72 hexanucleotide repeat expansions.

Etiology & Pathophysiology

The final common pathway is motor neuron death by combined mechanisms:

1. Glutamate excitotoxicity → excess synaptic glutamate (defective EAAT2/astrocytic reuptake) causes calcium-mediated neuronal death. This is the rationale for riluzole.
2. Oxidative stress → SOD1 mutations impair free-radical handling.
3. Protein aggregation → cytoplasmic inclusions of TDP-43 (ubiquitinated, in >90% of sporadic ALS) and SOD1 aggregates.
4. Axonal transport defects, mitochondrial dysfunction, and neuroinflammation.

The pathological signature on histology is loss of anterior horn cells with Bunina bodies and ubiquitin/TDP-43 inclusions, plus degeneration of the corticospinal tracts.

High-yield: TDP-43 inclusions are the molecular hallmark of sporadic ALS and the pathological link to FTD. Bunina bodies are the classic eosinophilic intracytoplasmic inclusions in anterior horn cells.

UMN vs LMN — the core NEET PG distinction

This single table is the most examinable concept in the entire topic and explains nearly every MND clinical sign.

Feature	Upper motor neuron (UMN)	Lower motor neuron (LMN)
Weakness pattern	Pyramidal (extensors of arm, flexors of leg)	Focal, follows root/nerve/myotome
Tone	Increased (spasticity, clasp-knife)	Decreased (flaccid/hypotonia)
Bulk	Normal / disuse atrophy late	Marked wasting (early)
Reflexes	Exaggerated (hyperreflexia, clonus)	Diminished / absent
Plantar response	Extensor (Babinski +)	Flexor / absent
Fasciculations	Absent	Present
Abdominal reflexes	Lost (in cord lesions)	Preserved

High-yield: In MND, the cruel paradox is that a wasted, fasciculating muscle (LMN) shows brisk reflexes (UMN). Preserved or brisk reflexes in a clearly wasted limb should immediately raise MND.

Clinical Features

Onset is typically focal and asymmetric, then spreads to contiguous regions.

• Limb onset (~70%): asymmetric distal weakness — foot drop, tripping, or weak hand grip ("split hand" — preferential thenar/first dorsal interosseous wasting), painless. Fasciculations and cramps are early.
• Bulbar onset (~25%): dysarthria (slurred, then nasal/spastic speech), dysphagia, wasted fasciculating tongue, and emotional lability (pseudobulbar affect) when corticobulbar tracts are involved.
• Respiratory onset (rare): dyspnoea, orthopnoea, early morning headache (nocturnal hypoventilation).

Cardinal "spared" features (frequently the answer in MCQs):

High-yield — the "FOUR SPARES" of MND:

• Sensory system spared (no sensory loss — a key exclusion).
• Sphincter/bladder function spared (until very late).
• Extraocular muscles spared (eye movements normal — distinguishes from myasthenia).
• Cognition largely spared (though ~15% develop FTD).

Mnemonic for the spared systems: "MND keeps your Senses, Sphincters, Sight and Sense" (Sensation, Sphincter, eye movements, cognition).

A useful descriptive flow of disease evolution:

Focal asymmetric weakness + fasciculations → spread to contiguous regions → mixed UMN/LMN signs → bulbar involvement (dysarthria/dysphagia) → respiratory muscle failure → death (most commonly from respiratory failure/aspiration pneumonia).

Diagnosis & Investigation of Choice

MND is a clinical diagnosis supported by electrophysiology and confirmed by exclusion of mimics. There is no single confirmatory blood test.

Investigation of choice: Electromyography (EMG) / nerve conduction studies (NCS).

EMG demonstrates widespread active and chronic denervation in multiple regions while NCS show normal (or near-normal) sensory studies — confirming a pure motor, anterior-horn-cell process.

Test	Expected finding in MND
EMG	Fibrillations, positive sharp waves (active denervation); large, polyphasic, long-duration motor units; fasciculation potentials (chronic reinnervation)
NCS — motor	Reduced CMAP amplitude; normal conduction velocity (no demyelination)
NCS — sensory	Normal (key — excludes neuropathy)
MRI brain/spine	Done to exclude structural mimics (cord compression, syringomyelia); may show corticospinal T2 hyperintensity
Bloods	CK mildly raised; do TSH, B12, anti-GM1 (to exclude MMN), serum protein electrophoresis

High-yield: EMG should show denervation in at least 2–3 of 4 regions (bulbar, cervical, thoracic, lumbosacral) to support a diagnosis of ALS. Sensory NCS must be normal — abnormal sensory studies argue against MND.

El Escorial criteria (named criteria — frequently asked)

The revised El Escorial (World Federation of Neurology) criteria classify diagnostic certainty by combining UMN and LMN signs across body regions:

• Definite ALS: UMN + LMN signs in ≥3 regions.
• Probable ALS: UMN + LMN signs in ≥2 regions, with some UMN signs rostral to LMN signs.
• Probable (lab-supported): UMN + LMN in 1 region (or UMN alone in 1) + EMG denervation in ≥2 regions.
• Possible ALS: UMN + LMN signs in only 1 region.

The body is divided into four regions: bulbar, cervical, thoracic, lumbosacral. The newer Awaji criteria allow EMG fasciculation potentials to count as equivalent to clinical LMN signs, improving early sensitivity.

High-yield: "Definite ALS = UMN + LMN signs in 3 of 4 regions" is a classic one-liner. Remember the four regions: bulbar, cervical, thoracic, lumbosacral.

Management / Drug of Choice

MND has no cure; management is disease-modifying + multidisciplinary supportive + symptomatic.

Disease-modifying drug of choice — Riluzole

High-yield: Riluzole is the drug of choice and the only widely accepted disease-modifying agent in ALS. It is a glutamate-release inhibitor / antiglutamatergic agent (dose 50 mg BD) that prolongs survival by ~2–3 months and delays the need for tracheostomy. Monitor LFTs (hepatotoxicity is the main adverse effect; also nausea, asthenia).

Other agents:

• Edaravone (a free-radical scavenger / antioxidant): approved in some countries; modest slowing of functional decline in selected early patients.
• Sodium phenylbutyrate–taurursodiol and tofersen (an antisense oligonucleotide for SOD1-mutant ALS) are newer/targeted options for specific genotypes.

Multidisciplinary supportive care (the backbone)

• Respiratory: Non-invasive ventilation (NIV/BiPAP) is the intervention with the greatest survival benefit and improves quality of life when FVC falls (commonly <50% predicted or with nocturnal hypoventilation). Monitor with FVC and sniff nasal inspiratory pressure (SNIP).
• Nutrition: PEG (percutaneous endoscopic gastrostomy) for dysphagia/weight loss — ideally placed before FVC < 50% (safer).
• Symptomatic: baclofen/tizanidine for spasticity; quinine sulphate or other agents for cramps; anticholinergics (glycopyrrolate, amitriptyline) or botulinum toxin for sialorrhoea; amitriptyline / combination dextromethorphan–quinidine for pseudobulbar affect; opioids/benzodiazepines for terminal dyspnoea (palliative).
• Allied: physiotherapy, speech therapy, communication aids, and early advance-care/palliative planning.

High-yield: Two interventions that most influence survival/quality of life: riluzole (drug) and non-invasive ventilation (NIV). PEG protects against aspiration and malnutrition.

Complications

• Respiratory failure — the most common cause of death (from diaphragmatic/intercostal weakness).
• Aspiration pneumonia — from bulbar dysphagia.
• Malnutrition, weight loss, cachexia.
• Venous thromboembolism from immobility.
• Pseudobulbar affect (uncontrollable laughing/crying).
• Frontotemporal dementia in ~15% (ALS–FTD spectrum).
• Pressure sores, contractures, communication failure, and psychological distress/depression.

High-yield: Death in MND is most commonly due to respiratory failure (often during sleep from hypoventilation), with aspiration pneumonia a close contributor.

Key Differentials

Because MND is partly a diagnosis of exclusion, knowing its mimics is heavily tested.

Condition	Distinguishing feature from MND
Cervical spondylotic myelopathy	UMN signs in legs + LMN signs in arms — but sensory level present, neck pain, MRI cord compression
Multifocal motor neuropathy (MMN)	Pure LMN, conduction block on NCS, anti-GM1 antibodies +, responds to IVIG (important — treatable mimic)
Syringomyelia	Wasting of hands + dissociated (cape) sensory loss, preserved touch
Myasthenia gravis	Fatigable weakness, ptosis & diplopia (eye involvement), no wasting/UMN signs, decremental RNS
Spinal muscular atrophy (SMA)	Hereditary, pure LMN, younger onset, SMN1 gene
Kennedy disease (SBMA)	X-linked, LMN + gynaecomastia + sensory involvement, CAG repeat in androgen receptor
Inclusion body myositis	Asymmetric quadriceps + finger flexor weakness, raised CK, sensory normal but EMG myopathic
Lead/heavy-metal, thyrotoxic, hyperparathyroid myopathy	Reversible metabolic causes — screen and treat

High-yield: Always exclude two treatable mimics: cervical cord compression (do MRI) and multifocal motor neuropathy (anti-GM1, conduction block, treat with IVIG). Missing these is a classic clinical error.

Recently asked / exam angle

• "Wasting with brisk reflexes / fasciculations with extensor plantar" → answer is Motor neuron disease (ALS). The mixed UMN+LMN picture is the single most repeated theme.
• "No sensory loss + no bladder involvement + tongue fasciculations" → MND / progressive bulbar palsy.
• Drug questions: Only disease-modifying drug in ALS = Riluzole; mechanism = glutamate (release) inhibitor / antiglutamatergic; monitor = LFTs.
• Pathology/molecular: Inclusion bodies of sporadic ALS = TDP-43; anterior horn eosinophilic inclusions = Bunina bodies; commonest familial gene = C9orf72; classic first gene = SOD1.
• Criteria: Diagnostic criteria for ALS = El Escorial (revised) / Awaji; definite ALS = UMN+LMN in 3 of 4 regions.
• Investigation: Investigation of choice = EMG; sensory NCS in MND = normal.
• Best variant prognosis = PLS; worst = progressive bulbar palsy.
• Commonest cause of death = respiratory failure.
• Intervention with best survival benefit (non-pharmacological) = non-invasive ventilation (NIV).

Rapid revision

1. ALS = commonest MND (~80%); hallmark = mixed UMN + LMN signs in the same region.
2. Four spares: sensation, sphincters, eye movements, cognition (mostly) are preserved.
3. PLS = pure UMN (best prognosis); PMA = pure LMN; PBP = bulbar LMN (worst prognosis).
4. Wasting + fasciculations (LMN) with brisk reflexes + Babinski (UMN) = MND until proven otherwise.
5. Investigation of choice = EMG (widespread denervation, fasciculation potentials); sensory NCS normal.
6. El Escorial: definite ALS = UMN + LMN in 3 of 4 regions (bulbar, cervical, thoracic, lumbosacral).
7. Riluzole (50 mg BD) = only disease-modifying drug; antiglutamatergic; monitor LFTs; gains ~2–3 months survival.
8. NIV/BiPAP gives the greatest survival/quality-of-life benefit; PEG before FVC < 50%.
9. Molecular: TDP-43 inclusions (sporadic), Bunina bodies, genes C9orf72 > SOD1 > TARDBP/FUS.
10. Most common cause of death = respiratory failure (nocturnal hypoventilation, aspiration pneumonia).
11. Treatable mimics to exclude: cervical spondylotic myelopathy (MRI) and multifocal motor neuropathy (anti-GM1, IVIG).
12. ~15% of ALS overlap with frontotemporal dementia (ALS–FTD, C9orf72).